Lantheus Holdings Inc. (LNTH) Hits New 52-Week High at $8.58
Lantheus Holdings Inc. (NASDAQ:LNTH) hit a new 52-week high during trading on Monday . The stock traded as high as $8.58 and last traded at $8.33, with a volume of 452,374 shares changing hands. The stock had previously closed at $7.89.
LNTH has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Lantheus Holdings from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Friday, May 6th. Jefferies Group reissued a “buy” rating on shares of Lantheus Holdings in a research report on Wednesday, May 4th. Finally, Credit Suisse Group AG set a $4.00 price objective on shares of Lantheus Holdings and gave the stock a “hold” rating in a research report on Friday, August 5th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $5.80.
The stock has a 50 day moving average of $5.06 and a 200 day moving average of $2.91. The company has a market capitalization of $256.47 million and a P/E ratio of 9.53.
Lantheus Holdings (NASDAQ:LNTH) last posted its earnings results on Thursday, August 4th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.06 by $0.18. The business had revenue of $78 million for the quarter, compared to analyst estimates of $72.66 million. On average, analysts expect that Lantheus Holdings Inc. will post $0.53 EPS for the current fiscal year.
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.